Drugs / BL-M09D1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07056556 | Jul 2025 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06954077 | May 2025 → May 2027 expected | digestive system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-17 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M09D1（ADC）治疗晚期实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-17 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M09D1（ADC）治疗晚期实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M09D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07056556 ↗ |
| Route | Intravenous | “Administration by intravenous infusion for a cycle of 3 weeks.” NCT06954077 ↗ |